Abstract
Small cell lung cancer (SCLC) is a highly malignant tumor which is eventually refractory to any treatment. Intratumoral heterogeneity (ITH) may contribute to treatment failure. However, the extent of ITH in SCLC is still largely unknown. Here, we subject 120 tumor samples from 40 stage I-III SCLC patients to multi-regional whole-exome sequencing. The most common mutant genes are TP53 (88%) and RB1 (72%). We observe a medium level of mutational heterogeneity (0.30, range 0.0~0.98) and tumor mutational burden (TMB, 10.2 mutations/Mb, range 1.1~51.7). Our SCLC samples also exhibit somatic copy number variation (CNV) across all patients, with an average CNV ITH of 0.49 (range 0.02~0.99). In terms of mutation distribution, ITH, TMB, mutation clusters, and gene signatures, patients with combined SCLC behave roughly the same way as patients with pure SCLC. This condition also exists in smoking patients and patients with EGFR mutations. A higher TMB per cluster is associated with better disease-free survival while single-nucleotide variant ITH is linked to worse overall survival, and therefore these features may be used as prognostic biomarkers for SCLC. Together, these findings demonstrate the intratumoral genetic heterogeneity of surgically resected SCLC and provide insights into resistance to treatment.
Highlights
Small cell lung cancer (SCLC) is a highly malignant tumor which is eventually refractory to any treatment
While the vast majority of patients are sensitive to chemotherapy and radiotherapy at the time of the initial treatment, all patients inevitably face the dilemma of chemoresistance and disease progression[3]
Many small cell lung cancer (SCLC) patients are sensitive to initial treatment, but all patients inevitably face the dilemma of chemoresistance
Summary
Small cell lung cancer (SCLC) is a highly malignant tumor which is eventually refractory to any treatment. A higher TMB per cluster is associated with better disease-free survival while single-nucleotide variant ITH is linked to worse overall survival, and these features may be used as prognostic biomarkers for SCLC Together, these findings demonstrate the intratumoral genetic heterogeneity of surgically resected SCLC and provide insights into resistance to treatment. We aim to provide the intratumoral genetic heterogeneity landscape of surgically resected SCLC, by analyzing the whole-exome sequencing data of 120 samples from 40 patients with SCLC. We characterize their mutational burden, heterogeneity, evolution, and potential biomarkers.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have